Business Standard

Kiran Mazumdar support for pharma

BS Reporter  |  Chennai/ Chandigarh 

  • ALSO READ

    GM plans to sell 250 Sails every month in state

    EOW probes Rs 2,100-cr PSU loan to Manish Mehta's power venture

    Answers to last week's quiz (#279)

    Markets to make long-term gains

    'A'bad likely to have fresh office supply'

Kiran Mazumdar-Shaw, CMD, Ltd, has said that both developed countries and emerging markets were now moving towards generic drugs. She added, with India emerging as biggest and low-cost generic producer, it provides a huge opportunity for India to gain from the growing generic drugs market. She has also demanded that the cost of capital needs to be subsidised, since pharmaceutical was a capital intensive business. Generic drugs is expected to be 40 per cent (value terms) of the global pharmaceutical market by 2015.

Kiran Mazumdar support for pharma

Kiran Mazumdar-Shaw, CMD, Biocon Ltd, has said that both developed countries and emerging markets were now moving towards generic drugs. She added, with India emerging as biggest and low-cost generic producer, it provides a huge opportunity for India to gain from the growing generic drugs market. She has also demanded that the cost of capital needs to be subsidised, since pharmaceutical was a capital intensive business.

Kiran Mazumdar-Shaw, CMD, Ltd, has said that both developed countries and emerging markets were now moving towards generic drugs. She added, with India emerging as biggest and low-cost generic producer, it provides a huge opportunity for India to gain from the growing generic drugs market. She has also demanded that the cost of capital needs to be subsidised, since pharmaceutical was a capital intensive business. Generic drugs is expected to be 40 per cent (value terms) of the global pharmaceutical market by 2015.

image

Latest News